Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of acalabrutinib and obinutuzumab-based regimens in previously untreated chronic lymphocytic leukemia
2023-509348-84-00Phase 3Completed
- Sponsor
- Acerta Pharma
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Acalabrutinib plus obinutuzumab, Obinutuzumab plus chlorambucil and Acalabrutinib monotherapy (3 arms). Primary endpoint: Progression-free survival. Started Apr 2015; status: completed.
02
Drugs
acalabrutinibobinutuzumabchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-509348-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509348-84-00.